- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02214914
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers
August 29, 2018 updated by: Boehringer Ingelheim
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 5, 10, 25, 50, 100, 200 and 400 mg BI 11634 Solution Administered to Healthy Male Volunteers. Randomised, Double-blind, Placebo Controlled at Each Dose Level. Intra-individual Comparison of Solution to an Immediate Release Tablet Formulation at One Dose Level (50 mg)
First evaluation of safety, tolerability, pharmacokinetics and the pharmacodynamic effect of BI 11634 on coagulation parameters
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males according to the following criteria:
Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
- Age ≥18 and ≤50 years
- Haemoglobin within the normal ranges
- Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
- Signed and dated written informed consent prior to admission to the study in accordance with Good clinical practice (GCP) and the local legislation
Exclusion Criteria:
- Relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Relevant surgery of gastrointestinal tract
- History of any bleeding disorder or acute blood coagulation defect, for the subject itself or any person of his family as far as known
- History of gastric ulcera and cholecystectomy
- Occult blood in feces
- Relevant diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Relevant chronic or acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- Use of acetylsalicylic acid or any other non-steroidal anti-inflammatory drugs (NSAID) within 2 weeks of study start until the end of study
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Alcohol abuse (more than 40 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Vulnerable subjects (e.g. persons kept in detention)
- The subject is not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
- Subjects with a history within the past 2 weeks of closed head or torso trauma or deceleration injury such as an automobile accident or fall from a significant height
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: BI 11634 drinking solution
single rising dose
|
|
Experimental: BI 11634 tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with adverse events
Time Frame: up to 10 days after drug administration
|
up to 10 days after drug administration
|
Number of subjects with clinically significant findings in vital signs (blood pressure, pulse rate)
Time Frame: up to 10 days after drug administration
|
up to 10 days after drug administration
|
Number of subjects with clinically significant findings in ECG
Time Frame: up to 10 days after drug administration
|
up to 10 days after drug administration
|
Assessment of tolerability by investigator on a 4-point scale
Time Frame: up to 10 days after drug administration
|
up to 10 days after drug administration
|
Number of subjects with clinically significant findings laboratory tests
Time Frame: up to 10 days after drug administration
|
up to 10 days after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent inhibition of thrombin generation by BI 11634
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
|
Percent peak inhibition of thrombin generation
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
|
Time to maximum inhibition of thrombin generation BI 11634
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
|
Percent prolongation of lag time
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
|
Area under the inhibition of the endogenous thrombin generation-time curve
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
|
Cmax (maximum measured concentration of the analyte in plasma)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
t1/2 (terminal half-life of the analyte in plasma)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
MRTpo (mean residence time of the analyte in the body after oral administration)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
tmax (time from dosing to maximum measured concentration)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
λz (terminal rate constant in plasma)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
|
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
|
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
|
AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 up to the last quantifiable data point)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
CL/F (apparent clearance of the analyte in plasma after extravascular administration)
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
Activated partial thromboplastin time (aPTT) ratios between groups
Time Frame: up to 72 hours after drug administration
|
up to 72 hours after drug administration
|
|
Maximum aPTT prolongation
Time Frame: up to 72 hours after drug administration
|
compared between groups
|
up to 72 hours after drug administration
|
Maximum international normalized ratio (INR)
Time Frame: up to 72 hours after drug administration
|
compared between groups
|
up to 72 hours after drug administration
|
% inhibition of endogenous Factor Xa
Time Frame: up to 72 hours after drug administration
|
by Russel's Viper Venom test (RVV)
|
up to 72 hours after drug administration
|
Maximum prolongation of blood coagulation time
Time Frame: up to 72 hours after drug administration
|
by HepTest® (Haemachem Inc.) and COAMATIC® Heparin test (Chromogenix)
|
up to 72 hours after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Primary Completion (Actual)
March 1, 2007
Study Registration Dates
First Submitted
August 12, 2014
First Submitted That Met QC Criteria
August 12, 2014
First Posted (Estimate)
August 13, 2014
Study Record Updates
Last Update Posted (Actual)
August 31, 2018
Last Update Submitted That Met QC Criteria
August 29, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- 1234.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States